(Reuters) – British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow cancer called myelofibrosis.
A decision for the marketing authorization of the therapy, momelotinib, is expected by early 2024, GSK said in a statement.
(Reporting by Eva Mathews in Bengaluru; Editing by Sonia Cheema)
